Friday, July 10, 2026

biotech · Advanced Solid Tumor · Solid Tumor, Adult · IMMX

Immix Biopharma

Immix Biopharma is a biotech organization headquartered in Los Angeles, USA. It trades on NYSE under ticker IMMX. Primary therapeutic focus areas include Advanced Solid Tumor, Solid Tumor, Adult, Light Chain (AL) Amyloid

Los Angeles, USA HQ
2012 Founded
39 Employees
Public company Type
IMMX · NYSE Ticker
Company details
Status
Public
HQ
Los Angeles, USA
Founded
2012
Employees
39
Programs
3
Drugs
2
Patents
2
Clinical program

Imx-110

Phase 2 · small molecule · Solid Tumor, Adult

Imx-110 for Solid Tumor, Adult is a Phase 2 program (small_molecule) at Immix Biopharma with 1 ClinicalTrials.gov record(s).

← All Immix Biopharma projects Phase 2 small molecule active

Internal code IMX-110-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Immix Biopharma
Phase
Phase 2
Modality
small_molecule
Indication
Solid Tumor, Adult
Status
active
Trials
1

Clinical trials